JSC
DNLI icon

Jackson Square Capital’s Denali Therapeutics DNLI Stock Holding History

Jackson Square Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-620
Closed -$22K – 197
2020
Q3 		$22K Buy
+620
New +$18.7K 0.01% 214

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jackson Square Capital's DNLI Position: Q4 2020 in Review

Jackson Square Capital sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 620 shares — an estimated $22K sold.

Jackson Square Capital first reported a position in DNLI in Q3 2020 and held it in 1 quarter. The position peaked at $22K in Q3 2020. 204 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Jackson Square Capital reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Jackson Square Capital sold 620 Denali Therapeutics shares in Q4 2020, an estimated $22K.
  • Jackson Square Capital first reported a position in Denali Therapeutics in Q3 2020 and held it in 1 quarter.
  • Jackson Square Capital's Denali Therapeutics position peaked at $22K in Q3 2020.
  • 204 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Jackson Square Capital's 13F filing for Q4 2020, filed 5 Mar 2021.